Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment

April 4, 2024

https://www.globenewswire.com/news-release/2024/04/04/2858193/0/en/Sensei-Biotherapeutics-Announces-Nature-Communications-Publication-Describing-Mechanism-of-Action-of-SNS-101-Selectively-Targeting-the-Active-Form-of-VISTA-within-the-Tumor-Microen.html

BOSTON, April 04, 2024 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced the publication of a peer-reviewed research paper in Nature Communications. The research was conducted by scientists at Sensei Biotherapeutics in collaboration with genOway and the laboratory of Dr. Robert Schreiber at the Washington University, St. Louis School of Medicine.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.